/XERS

XERS Stock - Xeris Biopharma Holdings, Inc.

Q: What is the analyst price target for XERS?

Analyst price target information is not currently available for XERS.

Q: What is XERS's market cap?

Market capitalization information is not currently available for XERS.

Healthcare|Biotechnology|NASDAQ

$7.71-2.03%

$0.16 (-2.03%) • Jan 13

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

High Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+75.1%upside

Target: $13.50

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for XERS

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.94

52W High$10.08

52W Low$3.15

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$203.07M	$163.91M	$110.25M	$49.59M	$20.43M
Gross Profit	$166.24M	$135.27M	$87.61M	$36.27M	$11.11M
Gross Margin	81.9%	82.5%	79.5%	73.1%	54.4%
Operating Income	$-33,646,000	$-44,010,000	$-81,940,000	$-115,156,000	$-83,546,000
Net Income	$-54,836,000	$-62,255,000	$-94,660,000	$-122,725,000	$-91,140,000
Net Margin	-27.0%	-38.0%	-85.9%	-247.5%	-446.0%
EPS	$-0.37	$-0.45	$-0.70	$-1.55	$-2.14

Company Overview

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

Visit Website

Earnings History & Surprises

XERS

Beat Rate

61%

Last 18 quarters

Avg Surprise

+4.4%

EPS vs Estimate

Beats / Misses

11/7

Last 12 quarters

Latest EPS

$0.00

Q4 2025

EPS Surprise History

Q1 24

-11.1%

$-0.10vs$-0.09

Q2 24

-16.7%

$-0.14vs$-0.12

Q3 24

+9.1%

$-0.10vs$-0.11

Q4 24

+33.3%

$-0.06vs$-0.09

Q1 25

+62.5%

$-0.03vs$-0.08

Q2 25

+14.3%

$-0.06vs$-0.07

Q3 25

+66.7%

$-0.01vs$-0.03

Q4 25

-65.0%

$0.00vs$0.01

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	May 6, 2026	—	—	—	—
Q1 2026	Mar 2, 2026	$0.03	—	—	—
Q4 2025	Nov 6, 2025	$0.01	$0.00	-65.0%	✗ MISS
Q3 2025	Aug 7, 2025	$-0.03	$-0.01	+66.7%	✓ BEAT
Q2 2025	May 8, 2025	$-0.07	$-0.06	+14.3%	✓ BEAT
Q1 2025	Mar 6, 2025	$-0.08	$-0.03	+62.5%	✓ BEAT
Q4 2024	Nov 8, 2024	$-0.09	$-0.06	+33.3%	✓ BEAT
Q3 2024	Aug 8, 2024	$-0.11	$-0.10	+9.1%	✓ BEAT
Q2 2024	May 9, 2024	$-0.12	$-0.14	-16.7%	✗ MISS
Q1 2024	Mar 6, 2024	$-0.09	$-0.10	-11.1%	✗ MISS
Q4 2023	Nov 9, 2023	$-0.12	$-0.09	+25.0%	✓ BEAT
Q3 2023	Aug 8, 2023	$-0.13	$-0.14	-7.7%	✗ MISS
Q2 2023	May 9, 2023	$-0.17	$-0.12	+29.4%	✓ BEAT
Q1 2023	Mar 8, 2023	$-0.16	$-0.10	+37.5%	✓ BEAT
Q4 2022	Nov 9, 2022	$-0.17	$-0.14	+17.6%	✓ BEAT
Q3 2022	Aug 10, 2022	$-0.23	$-0.19	+17.4%	✓ BEAT
Q2 2022	May 11, 2022	$-0.24	$-0.25	-4.2%	✗ MISS
Q1 2022	Mar 10, 2022	$-0.21	$-0.42	-100.0%	✗ MISS
Q4 2021	Nov 10, 2021	$-0.37	$-0.36	+2.7%	✓ BEAT
Q3 2021	Aug 5, 2021	$-0.31	$-0.41	-32.3%	✗ MISS

Frequently Asked Questions about XERS

What is XERS's current stock price?

Xeris Biopharma Holdings, Inc. (XERS) is currently trading at $7.71 per share. The stock has moved -2.03% today.

What is the analyst price target for XERS?

The average analyst price target for XERS is $13.50, based on 1 analyst.

What sector is Xeris Biopharma Holdings, Inc. in?

Xeris Biopharma Holdings, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is XERS's market cap?

Xeris Biopharma Holdings, Inc. has a market capitalization of $1.28 billion, making it a small-cap company.

Does XERS pay dividends?

No, Xeris Biopharma Holdings, Inc. does not currently pay a dividend to shareholders.